IGF::OT::IGF tDCS to Reduce Craving in Cocaine Addiction. Base Award. SBIR Phase I. September 30, 2018 - May 29, 2019. N43DA-18-8948.

Soterix Medical,Inc., Woodbridge NJ

Investigators

Abstract

Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 164, the contractor will develop new or convert existing neuromodulatory technologies used for other indications to treat SUDs, in a manner that will facilitate wide application and enhance market penetration. The goal of this project is to fully develop a portable neuromodulatory intervention to reduce craving in cocaine addiction.